# Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

> **NCT04072835** · PHASE3 · COMPLETED · sponsor: **Milestone Pharmaceuticals Inc.** · enrollment: 1116 (actual)

## Conditions studied

- Paroxysmal Supraventricular Tachycardia

## Interventions

- **DRUG:** Etripamil NS

## Key facts

- **NCT ID:** NCT04072835
- **Lead sponsor:** Milestone Pharmaceuticals Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-01-26
- **Target enrollment:** 1116 (ACTUAL)
- **Last updated:** 2024-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072835, "Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04072835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*